scholarly journals Liver Resection and Surgical Strategies for Management of Primary Liver Cancer

2018 ◽  
Vol 25 (1) ◽  
pp. 107327481774462 ◽  
Author(s):  
Sonia T. Orcutt ◽  
Daniel A. Anaya
Keyword(s):  
Liver Resection ◽  
Liver Cancer ◽  
Liver Function ◽  
Surgical Resection ◽  
Primary Liver Cancer ◽  
Curative Intent ◽  
Surgical Strategies ◽  
Prognostic Features ◽  
Complex Anatomy ◽  
Number Of Patients

Primary liver cancer—including hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC)—incidence is increasing and is an important source of cancer-related mortality worldwide. Management of these cancers, even when localized, is challenging due to the association with underlying liver disease and the complex anatomy of the liver. Although for ICC, surgical resection provides the only potential cure, for HCC, the risks and benefits of the multiple curative intent options must be considered to individualize treatment based upon tumor factors, baseline liver function, and the functional status of the patient. The principles of surgical resection for both HCC and ICC include margin-negative resections with preservation of adequate function of the residual liver. As the safety of surgical resection has improved in recent years, the role of liver resection for HCC has expanded to include selected patients with preserved liver function and small tumors (ablation as an alternative), tumors within Milan criteria (transplant as an alternative), and patients with large (>5 cm) and giant (>10 cm) HCC or with poor prognostic features (for whom surgery is infrequently offered) due to a survival benefit with resection for selected patients. An important surgical consideration specifically for ICC includes the high risk of nodal metastasis, for which portal lymphadenectomy is recommended at the time of hepatectomy for staging. For both diseases, onco-surgical strategies including portal vein embolization and parenchymal-sparing resections have increased the number of patients eligible for curative liver resection by improving patient outcomes. Multidisciplinary evaluation is critical in the management of patients with primary liver cancer to provide and coordinate the best treatments possible for these patients.

scholarly journals Application of Traditional Chinese Medicine Combined with TACE in Patients with Primary Hepatocellular Carcinoma and Its Effect on Liver Function

1970 ◽  
Vol 1 (2) ◽  
Author(s):  
Haibin Ding
Keyword(s):  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Liver Cancer ◽  
Liver Function ◽  
Recurrence Rate ◽  
Transcatheter Arterial Chemoembolization ◽  
Primary Liver Cancer ◽  
Control Group ◽  
Experimental Group ◽  
Arterial Chemoembolization

Objective: To analyze the effects of Chinese herbal medicine combined with transcatheter arterial chemoembolization (TACE) on liver function in patients with primary hepatocellularCarcinoma (HCC). Methods: 122 patients with primary hepatocellular carcinoma admitted in our hospital from March 2014 to October 2016 were divided into experimental group and control group according to the digital table. The number of each group was the same. The patients in the control group were treated by transcatheter arterial chemoembolization. The experimental group was treated with traditional Chinese medicine on the basis of the control group. SPSS20.0 statistical software for statistical analysis of two groups of patients with short-term effect, follow-up of one year primary liver cancer recurrence rate, before and after treatment WBC count, liver function (alanine aminotransferase), alpha-fetoprotein and Karnofsky index parameters. Results: ①The total effective rate of the experimental group was significantly higher than that of the control group (P <0.05); ②The relapse rate of theexperimental group was significantly lower than that of the control group (P <0.05); ③ Before the treatment, the patients in the two groups had significantly higher recurrence rate than those in the control group (P <0.05). After treatment, the white blood cell count, liver function and alpha-fetoprotein levels in the experimental group were significantly better than those in thecontrol group (P <0.05), but no significant difference was found between the two groups (P<0.05). ④ The Karnofsky score of the experimental group was significantly higher than that of the control group (P<0.05). Conclusion: Chinese medicine combined with transcatheter arterial chemoembolization in patients with primary liver cancer in the application value is relatively high.

Iatrogenic spreading of liver derived cells by liver resection and needle biopsy in patients with primary liver cancer

1998 ◽  
Vol 28 ◽  
pp. 91
Author(s):  
M. Louha ◽  
J. Nicolet ◽  
M. Sabile ◽  
H. Zylberberg ◽  
C. Vons ◽  
...  
Keyword(s):  
Liver Resection ◽  
Liver Cancer ◽  
Needle Biopsy ◽  
Primary Liver Cancer

Treatment of Hepatocellular Carcinoma

2016 ◽  
Vol 34 (5) ◽  
pp. 597-602 ◽  
Author(s):  
Álvaro Díaz-González ◽  
María Reig ◽  
Jordi Bruix
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cancer ◽  
Liver Function ◽  
Primary Liver Cancer ◽  
Performance Status ◽  
Intermediate Stage ◽  
Extrahepatic Disease ◽  
Stage Migration ◽  
Advanced Stage ◽  
Tumour Burden

Hepatocellular carcinoma (HCC) represents the most frequent primary liver cancer. This disease usually arises as a result of a chronic liver disease, but may appear without any underlying disease. In most units, the staging and treatment decision in patients with HCC follows the Barcelona Clínic Liver Cancer (BCLC) strategy. Following this approach, patients diagnosed with HCC are classified according to tumour burden, liver function and ECOG-Performance Status (PS). This stratifies patients according to prognosis and links each stage with the evidence-based treatment approach to be first considered. Patients correspond to BCLC stage 0 (very early) when the tumour burden accounts for just one nodule and it measures 2 cm or less. BCLC stage A includes patients with just one nodule or 3 nodules under 3 cm. Both stages 0 and A gather patients with preserved liver function according to Child-Pugh score, being Child-Pugh A. Patients in BCLC B stage (intermediate stage) are patients with multinodular liver cancer confined to the liver, without extrahepatic disease, ECOG-PS 0 and preserved liver function (Child-Pugh A or B). Patients with portal venous invasion, extrahepatic disease or cancer-related symptoms measured by PS (1-2) and still with preserved liver function correspond to BCLC C (advanced) stage. Finally, patients classified in BCLC stage D are those with a severe alteration of liver function (Child-Pugh C) or severe cancer-related symptoms with PS above 2. In very early and early stages (BCLC 0 and A), treatment options include surgical treatment, ablation and liver transplantation. Intermediate stage (BCLC B) patients should be considered for transarterial chemoembolization. At advanced stage (BCLC C), the recommended treatment is sorafenib. Finally, at the end stage (BCLC D), symptomatic treatment is the suggested option. The treatment stage migration concept refers to patients who at first glance would be treated with the option that corresponds to their BCLC stage but, because of any coexisting comorbidity, technical issue or even treatment failure/progression but still within the original stage cannot be treated by the initial suggested treatment. These patients then move to the treatment that would correspond to the next stage/s.

Surgery and Local Treatments of Liver Metastases from Colorectal Cancer: How to Improve Results

2003 ◽  
Vol 92 (1) ◽  
pp. 90-96 ◽  
Author(s):  
C. Penna ◽  
B. Nordlinger
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Surgical Resection ◽  
Preoperative Chemotherapy ◽  
Curative Intent ◽  
Number Of Patients ◽  
Ablative Techniques ◽  
Bilateral Lesions

Over the last 30 years, the benefits of surgical resection for liver metastases have been established. Actually, surgical resections are feasible with a very low mortality and 5-year survival that approaches 40 %. However, even if progresses in surgery and anaesthesiology now render possible extensive resections with removal of large, numerous or bilateral lesions, only 10 to 20 % of patients are candidate to surgery. The others gain benefit from chemotherapy with more and more active drugs. To improve this overall picture, efforts have been made to increase the number of patients that could be candidates for surgery. Shrinkage of tumours after administration of preoperative chemotherapy and availability of ablative techniques now permit to treat with curative intent metastases initially considered as non-resectable.

scholarly journals Clinical Observation of Laparoscopic Anatomic Hepatectomy for Early Primary Liver Cancer

2021 ◽  
Vol 233 ◽  
pp. 02026
Author(s):  
Yan Shaoxiong ◽  
Shen Shiheng
Keyword(s):  
Liver Resection ◽  
Liver Cancer ◽  
Clinical Effect ◽  
Liver Tumors ◽  
Primary Liver Cancer ◽  
Rapid Development ◽  
Operation Time ◽  
Clinical Results ◽  
Early Primary ◽  
Malignant Liver

At present, liver resection is the most effective treatment for malignant liver tumors, and with the rapid development of medical technology, anatomical liver resection has been widely used in clinical practice. This paper mainly studies the clinical effect of laparoscopic anatomic hepatectomy in the treatment of early primary liver cancer. According to the surgical method, the patients were divided into anatomic and non-anatomic hepatectomy groups. Preoperative, intraoperative and postoperative efficacy data of the two groups were analyzed. According to the clinical results, the anatomical resection of liver cancer has short operation time, fewer postoperative complications, fast recovery of liver function, and long survival time without tumor, with obvious clinical effect and definite curative effect, which is worthy of promotion.

The impact of hepatic fiblosis on the incidence of liver metastasis from colorectal cancer.

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 529-529
Author(s):  
Takayuki Kondo ◽  
Koji Okabayashi ◽  
Hirotoshi Hasegawa ◽  
Masashi Tsuruta ◽  
Ryo Seishima ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastasis ◽  
Surgical Resection ◽  
Hepatic Fibrosis ◽  
Disease Free Survival ◽  
Curative Intent ◽  
Alcoholic Fatty Liver ◽  
Hepatic Recurrence ◽  
Number Of Patients ◽  
The Impact

529 Background: Non-alcoholic steatohepatitis (NASH) is closely associated with hepatic fibrosis (HF). The number of patients who have NASH is increasing by eating high-calorie diet. It remains unclear how much impact such NASH and HF on the development of liver metastasis by colorectal cancer (CRC). The objectives of this study is to clarify the influence of HF on metachronous liver-specific recurrence in colorectal cancer patients who underwent colorectal surgery with curative intent. Methods: Between 2000 and 2010, patients who underwent a curative surgical resection for CRC were included in this study. We evaluated the progression of HF by using non-alcoholic fatty liver disease fibrosis score (NFS) based on preoperative blood test result, age, BMI and DM. The patients with NFS higher than 0.676 were objectively defined as HF. The influence of HF on hepatic recurrence was assessed by survival analyses. Results: A total of 953 CRC patients were enrolled, comprised of 293 in stage I, 327 in stage II and 333 in stage III. The mean of NFS was 1.32±1.55, where the included patients were categorized into 77 HF and 876 non-HF. 5-year liver-specific disease-free survival rate in HF was significantly poorer than non-HF (HS 87.0% vs. non-HF 94.5%, log-rank p=0.009). Multivariate analysis demonstrated that HF significantly promoted liver-specific recurrence compared to non-HF (HR=2.16, 95% CI, 1.00 to 4.64; p=0.049). Conclusions: Hepatic fibrosis had a great impact on hepatic recurrence after curative surgical resection of CRCs. These findings indicated that HF might be a favorable microenvironment in developing colorectal liver metastasis. The evaluation of the degree of HF can be useful in selection of adjuvant chemotherapy and postoperative surveillance.

Results of liver resection for primary liver cancer

1994 ◽  
Vol 1 (2) ◽  
pp. 118-122 ◽  
Author(s):  
Xin Da Zhou ◽  
Ye Qin Yu ◽  
Zhao You Tang ◽  
Zeng Chen Ma
Keyword(s):  
Liver Resection ◽  
Liver Cancer ◽  
Primary Liver Cancer ◽  
Results Of Liver Resection
Sign in / Sign up

Export Citation Format

Share Document